Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

Poly ADP Ribose Polymerase (PARP) Inhibitors Sales to Exhibit Significant CAGR Through 2026; Investments in Cures for Cancer to Drive Wider Adoption, Reports Future Market Insights

Published by linker 5

Posted on February 3, 2021

Featured image for article about Research Reports

The global poly ADP ribose polymerase (PARP) inhibitors market is poised for an exponential growth at a CAGR of 15% during the forecast period (2019-2026). Strong demand from the flourishing pharmaceutical industries a key contributor for this growth projection. PARP inhibitors have gained noteworthy momentum owing to increased awareness about efficacy in terms of treating different types of cancer.

“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period,” forecasts the FMI report.

Request sample of this report at https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

Key Takeaways of PARP Inhibitors Market Study

Olaparib is projected to dominate the global PARP inhibitors market owing to its applications in ovarian cancer, breast cancer, and pancreatic cancer.
A number of PARP inhibitors are up for imminent approval owing to a new drug application process.
PARP inhibitors are rapidly gaining traction as a new care standard of ovarian cancer treatment following platinum chemotherapy.
North America and Europe are projected to remain the dominant regional PARP inhibitors markets owing to better access to new technology and reimbursement policies.
Centralizing access to virtual and physical care with the aid of startups, research institutes and government bodies will play a key role in role for the future.

PARP Inhibitors Market – Top Growth Drivers

The rising burden of the different cancer types is a key driver behind the demand for PARP inhibitors.
The superior efficacy of PARP inhibitors over that of other cancer treatments is expected to drive revenue generation in the forecast period.
Faster approval of PARP inhibitor drugs are also anticipated to drive adoption rates, as demand rises.

PARP Inhibitors Market – Key Restraints

High costs related to clinical trials, insurance coverage, and testing for drug-drug interactions is a key restraint, particularly for emerging players.
The nascent nature of the PARP inhibitors market also builds the risk of such dosages not being included in select electronic records.

Schedule a meeting with expert analysts for detailed insights https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-3197

Competitive Landscape

Some of the key market players profiled in the report include, but are not limited to TESARO Inc., AbbVie Inc., Pfizer Inc., AstraZeneca, CLOVIS ONCOLOGY. Mergers and acquisitions are the key developmental strategies being adopted by leading market players, as the market is projected to remain in a consolidated stage through the forecast period. Such moves will enable manufacturers to widen their scope of regional product offerings. For instance, TESARO Inc., was acquired by Glaxo Smith Kline plc which allowed the latter to expand its product portfolio with the inclusion of Zejula (Niraparib) PARP inhibitor.